ArriVent BioPharma posts Q3 2025 results update

ArriVent BioPharma, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. On November 10, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.

The company specifies that the press release and the related disclosure are being furnished rather than filed under U.S. securities laws, meaning they are not subject to certain liability provisions and are not automatically incorporated into other SEC filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ArriVent BioPharma (AVBP) disclose in this Form 8-K?

ArriVent BioPharma, Inc. disclosed that it issued a press release announcing its financial results for the third quarter ended September 30, 2025, which is attached as Exhibit 99.1.

What period do the ArriVent BioPharma (AVBP) results in this filing cover?

The results described in the press release relate to ArriVent BioPharma’s financial performance for the third quarter ended September 30, 2025.

How is the ArriVent BioPharma (AVBP) Q3 2025 press release treated under securities laws?

The company states that the information in Item 2.02 and in Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liabilities under Section 18 of the Exchange Act and is not automatically incorporated by reference into other SEC filings.

Which exhibit contains ArriVent BioPharma’s (AVBP) Q3 2025 financial results?

Exhibit 99.1 to this Form 8-K contains the press release dated November 10, 2025, which announces ArriVent BioPharma’s third quarter 2025 financial results.

Who signed this ArriVent BioPharma (AVBP) Form 8-K?

The Form 8-K was signed on behalf of ArriVent BioPharma, Inc. by Winston Kung, the company’s Chief Financial Officer and Treasurer.

On what date did ArriVent BioPharma (AVBP) issue the Q3 2025 results press release?

ArriVent BioPharma issued the press release announcing its third quarter 2025 financial results on November 10, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/10/2025 - 08:00 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41929		86-3336099
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

18 Campus Boulevard, Suite 100

Newtown Square, PA

19073

(Address of principal executive offices)

(zip code)

Registrant’s telephone number, including area code: (628) 277-4836

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	AVBP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.		Description
99.1		Press Release dated November 10, 2025.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ARRIVENT BIOPHARMA, INC.

	By:	/s/ Winston Kung
		Winston Kung
		Chief Financial Officer and Treasurer

Date: November 10, 2025

Source: View Original Filing on SEC EDGAR